(Q73715625)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

1 reference

1 reference

A Mitsuda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

T Suou

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Y Ikuta

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

H Kawasaki

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 April 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

666-672

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Selective inhibition of human diploid fibroblast collagen synthesis by interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon-alpha, -beta, and -gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha. Comparison with histological changes in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Connective tissue biology and hepatic fibrosis: report of a conference

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Role of Ito cells in the degradation of matrix in liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Tissue inhibitors of matrix metalloendopeptidases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

TIMP expression in toxic and cholestatic liver injury in rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Comparison of matrix metalloproteinase expression in normal and cirrhotic human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980230-5

7 January 2021

10.1016/S0168-8278(00)80230-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10782917%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference